日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial

MAT2A抑制剂AG-270/S095033治疗晚期恶性肿瘤患者:一项I期试验

Gounder, Mrinal; Johnson, Melissa; Heist, Rebecca S; Shapiro, Geoffrey I; Postel-Vinay, Sophie; Wilson, Frederick H; Garralda, Elena; Wulf, Gerburg; Almon, Caroline; Nabhan, Salah; Aguado-Fraile, Elia; He, Peng; Romagnoli, Mathilde; Hossain, Mohammad; Narayanaswamy, Rohini; Sadou-Dubourgnoux, Amel; Cooper, Michael; Askoxylakis, Vasileios; Burris, Howard A; Tabernero, Josep

Genetic and oncogenic features of RASGRF fusions.

RASGRF融合的遗传和致癌特征

Das Sreya, Lenchner Daniel S, Jaeger Ellen, Hunihan Lisa, DeSantis Dana F, Fragkogianni Stamatina, Ronski Karyn, Wilson Frederick H

Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study

通过在线肿瘤委员会向社区肿瘤医生提供美国国家癌症研究所指定的综合癌症中心知识:一项纵向观察研究

Kalra, Maitri; Henry, Elizabeth; McCann, Kelly; Karuturi, Meghan S; Bustamante Alvarez, Jean G; Parkes, Amanda; Wesolowski, Robert; Wei, Mei; Mougalian, Sarah S; Durm, Gregory; Qin, Angel; Schonewolf, Caitlin; Trivedi, Meghna; Armaghani, Avan J; Wilson, Frederick H; Iams, Wade T; Turk, Anita A; Vikas, Praveen; Cecchini, Michael; Lubner, Sam; Pathak, Priyadarshini; Spencer, Kristen; Koshkin, Vadim S; Labriola, Matthew K; Marshall, Catherine H; Beckermann, Katy E; Sharifi, Marina N; Bejjani, Anthony C; Hotchandani, Varsha; Housri, Samir; Housri, Nadine

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

帕博利珠单抗治疗非小细胞肺癌脑转移患者:一项非随机、开放标签的 II 期试验的长期结果和生物标志物分析

Goldberg, Sarah B; Schalper, Kurt A; Gettinger, Scott N; Mahajan, Amit; Herbst, Roy S; Chiang, Anne C; Lilenbaum, Rogerio; Wilson, Frederick H; Omay, Sacit Bulent; Yu, James B; Jilaveanu, Lucia; Tran, Thuy; Pavlik, Kira; Rowen, Elin; Gerrish, Heather; Komlo, Annette; Gupta, Richa; Wyatt, Hailey; Ribeiro, Matthew; Kluger, Yuval; Zhou, Geyu; Wei, Wei; Chiang, Veronica L; Kluger, Harriet M

Larotrectinib in NTRK-Rearranged Solid Tumors(Published as part of the Biochemistry series "Biochemistry to Bedside")

拉罗替尼治疗 NTRK 重排实体瘤(作为“从生物化学到临床”生物化学系列的一部分发表)

Wilson, Frederick H; Herbst, Roy S

ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation

ERBB信号通路中断:靶向配体诱导的通路激活

Wilson, Frederick H; Politi, Katerina

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

MTAP缺失导致癌细胞对PRMT5精氨酸甲基转移酶的依赖性增强。

Kryukov, Gregory V; Wilson, Frederick H; Ruth, Jason R; Paulk, Joshiawa; Tsherniak, Aviad; Marlow, Sara E; Vazquez, Francisca; Weir, Barbara A; Fitzgerald, Mark E; Tanaka, Minoru; Bielski, Craig M; Scott, Justin M; Dennis, Courtney; Cowley, Glenn S; Boehm, Jesse S; Root, David E; Golub, Todd R; Clish, Clary B; Bradner, James E; Hahn, William C; Garraway, Levi A

WNK4 regulates activity of the epithelial Na+ channel in vitro and in vivo

WNK4在体外和体内均能调节上皮细胞Na+通道的活性。

Ring, Aaron M; Cheng, Sam X; Leng, Qiang; Kahle, Kristopher T; Rinehart, Jesse; Lalioti, Maria D; Volkman, Heather M; Wilson, Frederick H; Hebert, Steven C; Lifton, Richard P

WNK3, a kinase related to genes mutated in hereditary hypertension with hyperkalaemia, regulates the K+ channel ROMK1 (Kir1.1)

WNK3 是一种与遗传性高血压伴高钾血症突变基因相关的激酶,它调节 K+ 通道 ROMK1 (Kir1.1) 。

Leng, Qiang; Kahle, Kristopher T; Rinehart, Jesse; MacGregor, Gordon G; Wilson, Frederick H; Canessa, Cecilia M; Lifton, Richard P; Hebert, Steven C

WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis

WNK3激酶是NKCC2和NCC的正向调节因子,NKCC2和NCC是肾脏阳离子-氯离子共转运蛋白,对维持正常血压稳态至关重要。

Rinehart, Jesse; Kahle, Kristopher T; de Los Heros, Paola; Vazquez, Norma; Meade, Patricia; Wilson, Frederick H; Hebert, Steven C; Gimenez, Ignacio; Gamba, Gerardo; Lifton, Richard P